CONTEXT: Development of gallstones (GS) is reported during the use of somatostatin analogs (SA) that are at present the mainstay for the medical treatment of acromegaly. OBJECTIVE: To review the prevalence and clinical and biochemical correlates of GS in acromegalic patients. DESIGN AND SETTING: Retrospective survey on hospital records in acromegalic patients followed up in the last 20 yr in tertiary referral centers. PATIENTS: Four hundred and fifty-nine patients (272 females). MAIN OUTCOME MEASURES: According to SA use and GS occurrence, patients were divided in 4 groups: 1) treated with SA without GS (SA+GS-), 2) GS developed while on SA (SA+GS+), 3) GS without SA use (SA-GS+), 4) neither GS nor SA (SA-GS-). RESULTS: Patients were unevenly distributed in the 4 groups: 232, 125, 38, 64, respectively, pointing to a prevalence of GS in acromegaly of 8.3% at diagnosis with an additional 35% developing GS during SA. GS occurred after 3 months-18 yr (median 3 yr) of SA treatment, were diagnosed after symptoms in 17.6%, were associated to steatosis, ultrasound biliary dilation, and biochemical cholestasis, in 25.6%, 12.8%, and 4% of patients, respectively. Ursodehoxicolic acid was administered after GS occurrence, causing their dissolution in 39% of patients after 3-48 months (median 12). Cholecystectomy was performed in 16.8%of patients in group 2. At multivariate analysis obesity, dyslipidemia, and SA treatment were independent predictors of GS onset, whereas gender and age were not. CONCLUSIONS: GS are a frequent occurrence in acromegalic patients treated with SA, may occur at any time, but are seldom symptomatic or prompt acute surgery. Obesity and dyslipidemia appear to play a major role in the occurrence of GS in acromegalic patients on SA treatment.
CONTEXT: Development of gallstones (GS) is reported during the use of somatostatin analogs (SA) that are at present the mainstay for the medical treatment of acromegaly. OBJECTIVE: To review the prevalence and clinical and biochemical correlates of GS in acromegalicpatients. DESIGN AND SETTING: Retrospective survey on hospital records in acromegalicpatients followed up in the last 20 yr in tertiary referral centers. PATIENTS: Four hundred and fifty-nine patients (272 females). MAIN OUTCOME MEASURES: According to SA use and GS occurrence, patients were divided in 4 groups: 1) treated with SA without GS (SA+GS-), 2) GS developed while on SA (SA+GS+), 3) GS without SA use (SA-GS+), 4) neither GS nor SA (SA-GS-). RESULTS:Patients were unevenly distributed in the 4 groups: 232, 125, 38, 64, respectively, pointing to a prevalence of GS in acromegaly of 8.3% at diagnosis with an additional 35% developing GS during SA. GS occurred after 3 months-18 yr (median 3 yr) of SA treatment, were diagnosed after symptoms in 17.6%, were associated to steatosis, ultrasound biliary dilation, and biochemical cholestasis, in 25.6%, 12.8%, and 4% of patients, respectively. Ursodehoxicolic acid was administered after GS occurrence, causing their dissolution in 39% of patients after 3-48 months (median 12). Cholecystectomy was performed in 16.8%of patients in group 2. At multivariate analysis obesity, dyslipidemia, and SA treatment were independent predictors of GS onset, whereas gender and age were not. CONCLUSIONS:GS are a frequent occurrence in acromegalicpatients treated with SA, may occur at any time, but are seldom symptomatic or prompt acute surgery. Obesity and dyslipidemia appear to play a major role in the occurrence of GS in acromegalicpatients on SA treatment.
Authors: J P Tauber; M F Poncet; A G Harris; H R Barthel; C Simonetta-Chateauneuf; L Buscail; F Bayard Journal: J Clin Endocrinol Metab Date: 1995-11 Impact factor: 5.958
Authors: B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas Journal: J Clin Endocrinol Metab Date: 1998-10 Impact factor: 5.958
Authors: Nicole Brighi; Francesco Panzuto; Roberta Modica; Fabio Gelsomino; Manuela Albertelli; Sara Pusceddu; Sara Massironi; Giuseppe Lamberti; Maria Rinzivillo; Antongiulio Faggiano; Andrea Spallanzani; Diego Ferone; Natalie Prinzi; Roberta Elisa Rossi; Bruno Annibale; Anna Maria Colao; Davide Campana Journal: Oncologist Date: 2019-11-06
Authors: Nicole Brighi; Francesco Panzuto; Roberta Modica; Fabio Gelsomino; Manuela Albertelli; Sara Pusceddu; Sara Massironi; Giuseppe Lamberti; Maria Rinzivillo; Antongiulio Faggiano; Andrea Spallanzani; Diego Ferone; Natalie Prinzi; Roberta Elisa Rossi; Bruno Annibale; Anna Maria Colao; Davide Campana Journal: Oncologist Date: 2019-11-06
Authors: F Guaraldi; D Gori; G Beccuti; N Prencipe; R Giordano; Y Mints; V S Di Giacomo; A Berton; M Lorente; V Gasco; E Ghigo; R Salvatori; S Grottoli Journal: J Endocrinol Invest Date: 2016-05-06 Impact factor: 4.256
Authors: N Prencipe; C Bona; D Cuboni; M Parasiliti-Caprino; A M Berton; L M Fenoglio; V Gasco; E Ghigo; S Grottoli Journal: Pituitary Date: 2020-11-09 Impact factor: 4.107